Overview

Photodynamic and Pharmacologic Treatment of CNV

Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
0
Participant gender:
All
Summary
The goal of this pilot study is to validate the use of the combination of Lucentis (ranibizumab) and Visudyne (verteporfin) in the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and to explore the use of a volumetric analysis of the CNV lesion to determine disease activity, response to therapy, and as a tool for determining the need for retreatment.
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Mid-Atlantic Retina Consultations, Inc.
Treatments:
Ranibizumab
Verteporfin
Criteria
Inclusion Criteria:

- All previously untreated CNV secondary to MD